Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation
- PMID: 30580090
- DOI: 10.1016/j.cgh.2018.12.016
Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation
Abstract
Background & aims: Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL.
Methods: We collected data from 304 patients (mean age, 52.3 ± 12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection.
Results: The mean CLDQ overall score was 5.0 ± 1.2, with the lowest score in the category fatigue (4.3 ± 1.6) and the highest scores for activity (5.4 ± 1.4). Women had significantly lower CLDQ scores than men (4.6 ± 1.3 vs 5.3 ± 1.1; P < .001). We found negative correlations between CLDQ scores and presence of obesity (P < .001), type 2 diabetes (P < .001), and dyslipidaemia (P < .01). There was a negative correlation between level of aspartate aminotransferase, but not alanine aminotransferase, and HRQL. Higher histological score of steatosis (1 vs 3) resulted in lower mean CLDQ score (5.3 ± 1.1 vs 4.5 ± 1.4; P < .01); higher level of lobular inflammation (0 vs 3) also resulted in lower mean CLDQ score (5.3 ± 1.2 vs 3.9 ± 1.8; P <. 001). In contrast, advanced fibrosis (F3-4) compared to early or intermediate fibrosis (F0-2) had no significant effect on mean CLDQ score (4.9 ± 1.2 vs 5.1 ± 1.3; P = .072). In multivariate analysis, patients sex, age, presence of type 2 diabetes, and inflammation were independently associated with low HRQL.
Conclusion: In an analysis of data from the European NAFLD registry, we observed a substantial burden of symptoms in patients. In addition to age, sex, and the presence of diabetes, detection of lobular inflammation in biopsies correlated with lower HRQL.
Keywords: Cirrhosis; Emotional Function; Nonalcoholic Steatohepatitis; Patient-Reported Outcomes.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
PROs of Patient-reported Outcomes for Nonalcoholic Fatty Liver Disease and Effects on Treatment for Nonalcoholic Steatohepatitis.Clin Gastroenterol Hepatol. 2019 Sep;17(10):1950-1953. doi: 10.1016/j.cgh.2019.04.018. Epub 2019 Apr 10. Clin Gastroenterol Hepatol. 2019. PMID: 30981002 No abstract available.
Similar articles
-
Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.Clin Gastroenterol Hepatol. 2019 Sep;17(10):2093-2100.e3. doi: 10.1016/j.cgh.2019.01.001. Epub 2019 Jan 11. Clin Gastroenterol Hepatol. 2019. PMID: 30639779
-
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.JAMA Netw Open. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565. JAMA Netw Open. 2019. PMID: 31584681 Free PMC article.
-
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.Hepatology. 2025 Apr 1;81(4):1318-1327. doi: 10.1097/HEP.0000000000001084. Epub 2024 Sep 6. Hepatology. 2025. PMID: 39250515 Clinical Trial.
-
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.Am J Gastroenterol. 2019 Oct;114(10):1636-1641. doi: 10.14309/ajg.0000000000000375. Am J Gastroenterol. 2019. PMID: 31464743
-
Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.J Gastroenterol Hepatol. 2021 Mar;36(3):629-636. doi: 10.1111/jgh.15172. Epub 2020 Jul 16. J Gastroenterol Hepatol. 2021. PMID: 32627871 Review.
Cited by
-
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20. Gastroenterology. 2021. PMID: 34602251 Free PMC article. Review.
-
Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally.J Clin Transl Hepatol. 2021 Feb 28;9(1):71-80. doi: 10.14218/JCTH.2020.00082. Epub 2020 Dec 14. J Clin Transl Hepatol. 2021. PMID: 33604257 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression.Hepatol Commun. 2020 Jun 22;4(9):1293-1301. doi: 10.1002/hep4.1541. eCollection 2020 Sep. Hepatol Commun. 2020. PMID: 32923833 Free PMC article.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.J Clin Med. 2023 Sep 26;12(19):6216. doi: 10.3390/jcm12196216. J Clin Med. 2023. PMID: 37834859 Free PMC article. Review.
-
Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.Ther Adv Chronic Dis. 2022 Feb 23;13:20406223221077958. doi: 10.1177/20406223221077958. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35222903 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous